height. Further details about clinical and demographic data can be found in Table 1. In order to maximize signal detection, those with intermediate severity level sub-threshold PTSD were excluded. Other exclusion criteria included (i) any drug abuse within a year of assessment, (ii) lifetime schizophrenia, bipolar disorder, obsessive-compulsive disorder or other psychotic disorders, (iii) head injury with current post-concussion symptoms, (iv) trauma exposure within 3 months of assessment to exclude non-combat-associated PTSD, and (v) current suicidal or homicidal ideation. Of the genotyped subset, 116 participants are PTSD cases (CAPS range: 37–102, median: 65.5), whereas the other 128 are trauma exposed, age and ethnicity matched, healthy controls (CAPS range: 0–24, median: 2).Table 1Sample characteristics by PTSD status of SysBio cohort included in this studyPTSD cases (n = 128)Healthy controls (n = 116)P valueCAPS cur2.00 (0.00, 6.00)65.50 (51.75, 80.25)<0.001CAPS LT8.00 (3.00, 15.00)90.00 (77.75, 101.00)<0.001Female14% (18)14% (16)0.952BMI27.35 (24.45, 29.85)28.25 (25.61, 32.28)0.028Age30.00 (27.75, 37.00)31.00 (28.75, 36.25)0.338 Race/ethnicity Asian7% (9)3% (3) Black23% (30)29% (34) Hispanic28% (36)42% (49)0.026 White38% (49)24% (28) Other3% (4)2% (2) Education 12% (3)3% (4) 220% (26)35% (41) 324% (31)30% (35)0.009 435% (45)25% (29) 517% (22)6% (7) 61% (1)0% (0) BDI3.00 (0.00, 9.25)24.00 (16.50, 31.00)<0.001CAPS, Clinician Administered PTSD Scale (cur: current and LT:
